期刊
INFLAMMATORY BOWEL DISEASES
卷 13, 期 8, 页码 1024-1030出版社
OXFORD UNIV PRESS INC
DOI: 10.1002/ibd.20169
关键词
infliximab; lymphoma; thiopurines; Crohn's disease; pediatrics
Therapy for the inflammatory bowel diseases increasingly includes the use of immune-modifying and biologic therapies. Recently, in young patients with IBD, an association has been noted between the use of infliximab along with concomitant purine analogues and the development of hepatosplenic T-cell lymphoma (HSTCL)-a rare and all but incurable form of non-Hodgkin's lymphoma. This report briefly reviews the issue of lymphoma and IBD therapy. Additionally, a description of HSTCL and a summary of the known cases of this apparent therapeutic complication are presented. Clinical options in light of this new information are explored.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据